FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Paul McSheehy

Research Profile

Living Beings

Phenomena

Magnetic Resonance Spectroscopy

Chemicals & Drugs

Concepts & Ideas

Anatomy

Tumor Cell Line

Procedures

Disorders

Neoplasms

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
V Meier; C Geigy; N Grosse; Paul M J McSheehy; Carla Rohrer Bley
Use of epothilone B (patupilone) in refractory lymphoma and advanced solid tumors in dogs.
Carla Rohrer Bley; Angela Broggini-Tenzer; Polina Furmanova; Nicole Grosse; Paul M J McSheehy; Katrin Orlowski; Martin Pruschy
Microtubule stabilising agents and ionising radiation: multiple exploitable mechanisms for combined treatment.
Christoph Oehler; Martin Pruschy; Elisabeth J Rushing; Dirk Weber; Dorothea Weniger; Yasuhiro Yonekawa; Peter R Allegrini; Krisztina Barath; Angela Broggini-Tenzer; Karl Frei; Alexander Knuth; Urs M Lütolf; Paul M J McSheehy; Silvia Hofer
Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Paul McSheehy (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2013: V Meier; C Geigy; N Grosse; Paul M J McSheehy; Carla Rohrer Bley
Use of epothilone B (patupilone) in refractory lymphoma and advanced solid tumors in dogs.
Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 2013;27(1):120-5.
2013: Carla Rohrer Bley; Angela Broggini-Tenzer; Polina Furmanova; Nicole Grosse; Paul M J McSheehy; Katrin Orlowski; Martin Pruschy
Microtubule stabilising agents and ionising radiation: multiple exploitable mechanisms for combined treatment.
European journal of cancer (Oxford, England : 1990) 2013;49(1):245-53.
2012: Christoph Oehler; Martin Pruschy; Elisabeth J Rushing; Dirk Weber; Dorothea Weniger; Yasuhiro Yonekawa; Peter R Allegrini; Krisztina Barath; Angela Broggini-Tenzer; Karl Frei; Alexander Knuth; Urs M Lütolf; Paul M J McSheehy; Silvia Hofer
Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.
Oncology 2012;83(1):1-9.
2011: Anne-Christine Piguet; Vesna Radojevic; Bettina Saar; Marie V St-Pierre; Luigi Terracciano; Maresa Afthinos; Valentin Djonov; Ruslan Hlushchuk; Paul M J McSheehy; Jean-François Dufour
Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.
Molecular cancer therapeutics 2011;10(6):1007-17.
2011: Terry O'Reilly; Paul M J McSheehy; Markus Wartmann; Peter Lassota; Ralf Brandt; Heidi A Lane
Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.
Anti-cancer drugs 2011;22(1):58-78.
2011: Terence O'Reilly; Heidi A Lane; Jeanette M Wood; Christian R Schnell; Amanda Littlewood-Evans; Josef Brueggen; Paul M J McSheehy
Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model.
Cancer chemotherapy and pharmacology 2011;67(1):193-200.
2010: Terence O'Reilly; Paul M J McSheehy; R Kawai; O Kretz; L McMahon; Josef Brueggen; Armin Bruelisauer; H-P Gschwind; Peter R Allegrini; Heidi A Lane
Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents.
Cancer chemotherapy and pharmacology 2010;65(4):625-39.
2010: Paul M J McSheehy; Claudia Weidensteiner; Catherine Cannet; Stephane Ferretti; Didier Laurent; Stephan Ruetz; Michael Stumm; Peter R Allegrini
Quantified tumor t1 is a generic early-response imaging biomarker for chemotherapy reflecting cell viability.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(1):212-25.
2009: Stephane Ferretti; Peter R Allegrini; Mike M Becquet; Paul M J McSheehy
Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics.
Neoplasia (New York, N.Y.) 2009;11(9):874-81.
2009: Heidi A Lane; Jeanette M Wood; Paul M J McSheehy; Peter R Allegrini; Anne Boulay; Joseph Brueggen; Amanda Littlewood-Evans; Sauveur-Michel Maira; Georg Martiny-Baron; Christian R Schnell; Patrizia Sini; Terence O'Reilly
mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(5):1612-22.
2008: Terence O'Reilly; Markus Wartmann; Josef Brueggen; Peter R Allegrini; Andreas Floersheimer; Michel Maira; Paul M J McSheehy
Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
Cancer chemotherapy and pharmacology 2008;62(6):1045-54.
2006: Claudia Weidensteiner; Martin Rausch; Paul M J McSheehy; Peter R Allegrini
Quantitative dynamic contrast-enhanced MRI in tumor-bearing rats and mice with inversion recovery TrueFISP and two contrast agents at 4.7 T.
Journal of magnetic resonance imaging : JMRI 2006;24(3):646-56.
2006: Lucy Lee; Sunil Sharma; Bruno Morgan; Peter R Allegrini; Christian R Schnell; Josef Brueggen; Robert Cozens; Mark A Horsfield; Clemens Guenther; William P Steward; Joachim Drevs; David Lebwohl; Jeanette Wood; Paul M J McSheehy
Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
Cancer chemotherapy and pharmacology 2006;57(6):761-71.
2006: Paul Workman; Eric O Aboagye; Yuen-Li Chung; John R Griffiths; Rachel Hart; Martin Leach; Ross J Maxwell; Paul M J McSheehy; Patricia M Price; Jamal Zweit
Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.
Journal of the National Cancer Institute 2006;98(9):580-98.
2005: Stephane Ferretti; Peter R Allegrini; Terence O'Reilly; Christian R Schnell; Michael Stumm; Markus Wartmann; Jeanette Wood; Paul M J McSheehy
Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7773-84.
2005: Terence O'Reilly; Paul M J McSheehy; Fritz Wenger; Marc Hattenberger; Melanie Muller; Juliane Vaxelaire; Karl-Heinz Altmann; Markus Wartmann
Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo.
The Prostate 2005;65(3):231-40.
2005: Markus Rudin; Paul M J McSheehy; Peter R Allegrini; Martin Rausch; Diana Baumann; Mike Becquet; Karin Brecht; Josef Brueggen; Stephane Ferretti; Fabienne Schaeffer; Christian R Schnell; Jeanette Wood
PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
NMR in biomedicine 2005;18(5):308-21.
2005: Terence O'Reilly; Markus Wartmann; S-M Maira; Marc Hattenberger; Juliane Vaxelaire; M Muller; Stephane Ferretti; Elisabeth Buchdunger; Karl-Heinz Altmann; Paul M J McSheehy
Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma.
Cancer chemotherapy and pharmacology 2005;55(4):307-17.
2005: Paul M J McSheehy; R E Port; Loreta M Rodrigues; Simon P Robinson; Marion Stubbs; K van der Borns; G J Peters; Ian R Judson; Martin Leach; John R Griffiths
Investigations in vivo of the effects of carbogen breathing on 5-fluorouracil pharmacokinetics and physiology of solid rodent tumours.
Cancer chemotherapy and pharmacology 2005;55(2):117-28.
2004: Peter Traxler; Peter R Allegrini; Ralf Brandt; Josef Brueggen; Robert Cozens; Doriano Fabbro; Konstantina Grosios; Heidi A Lane; Paul M J McSheehy; Jürgen Mestan; Thomas Meyer; Careen Tang; Markus Wartmann; Jeanette Wood; Giorgio Caravatti
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Cancer research 2004;64(14):4931-41.
2003: Kristian Pietras; Michael Stumm; Martine Hubert; Elisabeth Buchdunger; Kristofer Rubin; Carl-Henrik Heldin; Paul M J McSheehy; Markus Wartmann; Arne Ostman
STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3779-87.
2003: Simon P Robinson; Paul F J W Rijken; Franklyn Arron Howe; Paul M J McSheehy; Boudewijn van der Sanden; Arend Heerschap; Marion Stubbs; Albert J van der Kogel; John R Griffiths
Tumor vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry.
Journal of magnetic resonance imaging : JMRI 2003;17(4):445-54.
2003: Paul M J McSheehy; Helen Troy; L R Kelland; Ian R Judson; Martin Leach; John R Griffiths
Increased tumour extracellular pH induced by Bafilomycin A1 inhibits tumour growth and mitosis in vivo and alters 5-fluorouracil pharmacokinetics.
European journal of cancer (Oxford, England : 1990) 2003;39(4):532-40.
2002: Loreta M Rodrigues; Simon P Robinson; Paul M J McSheehy; Marion Stubbs; John R Griffiths
Enhanced uptake of ifosfamide into GH3 prolactinomas with hypercapnic hyperoxic gases monitored in vivo by (31)P MRS.
Neoplasia (New York, N.Y.) 2002;4(6):539-43.
2002: John R Griffiths; Paul M J McSheehy; Simon P Robinson; Helen Troy; Yuen-Li Chung; Russell D Leek; Kaye J Williams; Ian J Stratford; Adrian L Harris; Marion Stubbs
Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1beta (HIF-1beta): evidence of an anabolic role for the HIF-1 pathway.
Cancer research 2002;62(3):688-95.
2001: John R Griffiths; Dominick J O McIntyre; Franklyn Arron Howe; Paul M J McSheehy; Loreta M Rodrigues; P Wadsworth; N M Price; F Lofts; G Nicholson; Kees Smid; Paul Noordhuis; G J Peters; Marion Stubbs
Issues of normal tissue toxicity in patient and animal studies--effect of carbogen breathing in rats after 5-fluorouracil treatment.
Acta oncologica (Stockholm, Sweden) 2001;40(5):609-14.
2000: Paul M J McSheehy; Martin Leach; Ian R Judson; John R Griffiths
Metabolites of 2'-fluoro-2'-deoxy-D-glucose detected by 19F magnetic resonance spectroscopy in vivo predict response of murine RIF-1 tumors to 5-fluorouracil.
Cancer research 2000;60(8):2122-7.
2000: Paul M J McSheehy; Marion Stubbs; John R Griffiths
Role of pH in tumor-trapping of the anticancer drug 5-fluorouracil.
Advances in enzyme regulation 2000;40():63-80.
2000: Marion Stubbs; Paul M J McSheehy; John R Griffiths; CL Bashford
Causes and consequences of tumour acidity and implications for treatment.
Molecular medicine today 2000;6(1):15-9.
1999: AS Ojugo; Paul M J McSheehy; Dominick J O McIntyre; C McCoy; Marion Stubbs; Martin Leach; Ian R Judson; John R Griffiths
Measurement of the extracellular pH of solid tumours in mice by magnetic resonance spectroscopy: a comparison of exogenous (19)F and (31)P probes.
NMR in biomedicine 1999;12(8):495-504.
1999: Marion Stubbs; Paul M J McSheehy; John R Griffiths
Causes and consequences of acidic pH in tumors: a magnetic resonance study.
Advances in enzyme regulation 1999;39():13-30.
1998: Paul M J McSheehy; Simon P Robinson; AS Ojugo; Eric O Aboagye; Mark Cannell; Martin Leach; Ian R Judson; John R Griffiths
Carbogen breathing increases 5-fluorouracil uptake and cytotoxicity in hypoxic murine RIF-1 tumors: a magnetic resonance study in vivo.
Cancer research 1998;58(6):1185-94.
1998: AS Ojugo; Paul M J McSheehy; Marion Stubbs; Glenn M Alder; CL Bashford; Ross J Maxwell; Martin Leach; Ian R Judson; John R Griffiths
Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells.
British journal of cancer 1998;77(6):873-9.
1997: Paul M J McSheehy; M T Seymour; AS Ojugo; Loreta M Rodrigues; Martin Leach; Ian R Judson; John R Griffiths
A pharmacokinetic and pharmacodynamic study in vivo of human HT29 tumours using 19F and 31P magnetic resonance spectroscopy.
European journal of cancer (Oxford, England : 1990) 1997;33(14):2418-27.
1997: Simon P Robinson; SJ Barton; Paul M J McSheehy; John R Griffiths
Nuclear magnetic resonance spectroscopy of cancer.
The British journal of radiology 1997;70 Spec No():S60-9.
1997: Simon P Robinson; Loreta M Rodrigues; AS Ojugo; Paul M J McSheehy; Franklyn Arron Howe; John R Griffiths
The response to carbogen breathing in experimental tumour models monitored by gradient-recalled echo magnetic resonance imaging.
British journal of cancer 1997;75(7):1000-6.
1997: Loreta M Rodrigues; Ross J Maxwell; Paul M J McSheehy; C R Pinkerton; Simon P Robinson; Marion Stubbs; John R Griffiths
In vivo detection of ifosfamide by 31P-MRS in rat tumours: increased uptake and cytotoxicity induced by carbogen breathing in GH3 prolactinomas.
British journal of cancer 1997;75(1):62-8.
1992: Paul M J McSheehy; M J Prior; John R Griffiths
Enhanced 5-fluorouracil cytotoxicity and elevated 5-fluoronucleotides in the rat Walker carcinosarcoma following methotrexate pre-treatment: a 19F-MRS study in vivo.
British journal of cancer 1992;65(3):369-75.
1991: Paul M J McSheehy; M Gervasoni; V Lampasona; E Erba; M D'Incalci
Studies of the differentiation properties of camptothecin in the human leukaemic cells K562.
European journal of cancer (Oxford, England : 1990) 1991;27(11):1406-11.
1989: Paul M J McSheehy; M J Prior; John R Griffiths
Methotrexate increases the activation and cytotoxicity of 5-fluorouracil: detected by 19F n.m.r. in vivo.
Biochemical Society transactions 1989;17(6):1050.
1989: Paul M J McSheehy; John R Griffiths
19F MRS studies of fluoropyrimidine chemotherapy. A review.
NMR in biomedicine 1989;2(4):133-41.
1989: Paul M J McSheehy; M J Prior; John R Griffiths
Prediction of 5-fluorouracil cytotoxicity towards the Walker carcinosarcoma using peak integrals of fluoronucleotides measured by MRS in vivo.
British journal of cancer 1989;60(3):303-9.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.